Eloxx Presents Positive Preclinical and Clinical Data of CF Therapy Candidate ELX-02
Eloxx Pharmaceuticals presented additional positive preclinical and clinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), reinforcing the therapy’s safety and tolerability in humans and its ability to increase the levels of CFTR protein in preclinical models of the disease. Findings were presented in three posters and…